Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 6/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.44 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610888 | 0.84 | ABL1 (0.54) | ABL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL3599324 | 0.84 | ABL1 (0.57) | ABL1XIAPMEN1KMT2AHSPD1 | |
| SCHEMBL3604738 | 0.84 | MEN1 (0.61) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL27768262 | 0.82 | ABL1 (0.43) | ABL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL3603727 | 0.82 | GSTO1 (0.60) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL3609158 | 0.81 | MEN1 (0.52) | ABL1XIAPMEN1KMT2ANPC1 | |
| SCHEMBL3604799 | 0.80 | ALOX5 (0.61) | ABL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL3604035 | 0.80 | ATP4A (0.56) | ABL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL3597550 | 0.80 | RRM1 (0.64) | ABL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL3597000 | 0.79 | MEN1 (0.73) | MEN1KMT2ANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
| EP-0089730-B1 | GUANIDINO HETEROCYCLICPHENYLAMIDINES, PROCESSES FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ISTITUTO DE ANGELI S.p.A. (IT) | 1987-05-27 | — | — | EP | disclosed |
| US-4645841-A | ANTIULCER AGENTS | ISTITUTO DE ANGELI, S.P.A. (IT) | 1987-02-24 | — | — | US | disclosed |
| US-4548944-A | ANTIULCER, ANTISECRETORY AGENTS | ISTITUTO DE ANGELI S.P.A. (IT) | 1985-10-22 | — | — | US | disclosed |
| EP-0089730-A2 | Guanidino heterocyclicphenylamidines, processes for their preparation and their pharmaceutical use | ISTITUTO DE ANGELI S.p.A. (IT) | 1983-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | ABL1 4507/4885XIAP 4640/4885MEN1 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.